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Introduction
Immune checkpoint inhibitors (ICIs) are designed to restore a 
patient’s antitumor immune response, which has been attenu-
ated during the process of tumor development. Antigen-
presenting cells normally express programmed death ligand 1 
(PD-L1) that, when bound by PD-1 on T cells, signal an 
exhausted active immune response. In cancers that express 
PD-L1 on tumor cells, PD-1 receptor expressed on T cells, B 
cells, and natural killer cells of an activated immune system, 
and the interaction of PD-1 and PD-L1 characterizes an adap-
tive and immune-evasive response by the tumor. This immune-
evasive interaction can be reversed by addition of ICIs that 
inhibit either molecule.1 Recently, agents that modulate the 
tumor immune response have provided durable clinical benefit 
to patients with late-stage or recurrent disease. Nivolumab 
(Opdivo) has received Food and Drug Administration (FDA) 
approval for the treatment of squamous and nonsquamous 
metastatic non–small-cell lung cancer (NSCLC) and meta-
static renal cell carcinoma with progression on or after chemo-
therapy.2 Nivolumab is a human IgG4 antibody that blocks 
programmed death 1 (PD-1) receptor and potentiates 
activation of T cells.3 Nivolumab therapy demonstrated 
improved tumor-related outcomes in multiple types of cancer.4 
Pembrolizumab (Keytruda), another PD-1 inhibitor, received 
FDA approval to treat advanced (metastatic) NSCLC whose 
disease has progressed after other treatments and with tumors 
that have 50% PD-L1 expression.5
Programmed death ligand 1 inhibition facilitates activation 
of potentially autoreactive T cells, leading to inflammatory 
adverse events across a range of tissues. Patients with a history 
of autoimmune diseases were excluded from clinical trials of 
PD-1 inhibitors.6 Exclusions included multiple sclerosis, auto-
immune neuropathy, Guillain-Barré syndrome, myasthenia 
gravis, systemic lupus erythematosus, connective tissue dis-
eases, scleroderma, inflammatory bowel disease, Crohn disease, 
ulcerative colitis, and hepatitis. Patients with rheumatoid 
arthritis, Sjögren syndrome, and psoriasis were included if dis-
ease was well-controlled. Although these therapies hold great 
promise, ICIs can trigger a variety of immune-related adverse 
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PuRPoSe: Immune checkpoint inhibition reactivates the immune response against cancer cells in multiple tissue types and has been 
shown to induce durable responses. However, for patients with autoimmune disorders, their conditions can worsen with this reactivation. We 
sought to identify, among patients with lung and renal cancer, how many harbor a comorbid autoimmune condition and may be at risk of 
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ditions were recorded.
ReSuLTS: More than 25% of patients with both lung and renal cancer had a comorbid autoimmune condition between 2010 and 2013 and 
were more likely to be women, older, and have more baseline comorbidities.
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events (irAEs). These include dermatologic, gastrointestinal, 
hepatic, endocrine, and other inflammatory conditions, and 
they are believed to result from general immune response 
enhancement.7 Khan et al8 have shown a relatively high rate of 
autoimmune diseases, approximately 14%, among patients with 
lung cancer, and these patients were more likely to be older 
women. The objective of this study was to confirm findings of 
Khan and colleagues in a more diverse cohort and identify 
whether patients with cancer with autoimmune disease exhibit 
different baseline characteristics and comorbidities.
Materials and Methods
We identified lung patients with and renal cancer using Truven 
Health MarketScan Commercial Claims and Medicare 
Supplemental Database. The MarketScan database includes 
approximately 40 million individuals from more than 160 large 
employers and health plans across the United States and 
includes health care claims with diagnosis and procedure codes 
for medical encounters and all prescription medication fills. 
These data are de-identified in compliance with the Health 
Insurance Portability and Accountability Act regulations, and 
the University of Kentucky Institutional Review Board 
approved the use of the database for this study.
Adults, 18 years and older, diagnosed with cancer between 
January 1, 2010 and November 31, 2013 were identified. At 
least 2 inpatient or outpatient diagnoses separated by at least 
14 days were required, and the date of the first qualifying diag-
nosis of cancer was defined as the index date. We directed our 
analyses to only lung and renal cancer due to the initial approv-
als of the ICI, nivolumab. Nivolumab received approval for the 
treatment of metastatic NSCLC on March 4, 2015 and for 
metastatic renal cell carcinoma on November 23, 2015. Patients 
were required to have at least 12 months of preindex and a 
minimum of 1-month postindex continuous enrollment in the 
database. We assessed patients for diagnosis of autoimmune 
diseases prior to or after diagnosis of cancer using International 
Classif ication of Diseases, Ninth Revision codes for 41 autoim-
mune diseases. It is necessary to assess autoimmune disease 
before and after diagnosis because newly diagnosed autoim-
mune conditions would still have bearing on therapeutic deci-
sion-making practices. Prevalence was determined by the 
presence of 2 or more claims to autoimmune diseases separated 
by at least 30 days. Baseline characteristics and Elixhauser and 
Charlson comorbidity indexes of patients with and without 
autoimmune diseases were compared. These indexes include 17 
and 31 categories of comorbid conditions, respectively, and 
have been widely used for risk adjustment with health out-
comes data.9,10 Two-sample t test and χ2 tests were conducted 
to assess significant differences between groups. Bonferroni 
correction was applied due to multiple comparisons.
Results and Discussion
We identified 53 783 patients with lung cancer and 27 349 
patients with renal cancer of whom 13 156 (24.5%) and 
8217 (30.1%) also had an autoimmune disease, respectively. 
Hypothyroidism (55.8%, 56.7%), rheumatoid arthritis (20.2%, 
18.1%), and type 1 diabetes mellitus (11.5%, 14.5%) were the 
most common for patients with both lung and renal cancers, 
respectively (Table 1). Baseline characteristics and comorbidi-
ties are listed in Table 2. Patients with cancer with autoimmune 
disease were more likely to be women, older, and had higher 
prevalence of comorbidities than patients with cancer without 
autoimmune disease (Table 2).
More than a quarter of patients diagnosed with lung and 
renal cancer were found to have a comorbid autoimmune con-
dition. When considering that immune checkpoint inhibition 
is only approved in late stages of cancer, it is not clear whether 
the benefits of pursuing treatment in patients with autoim-
mune disease outweigh the risk of inducing worse irAEs. 
Several case reports have been published showing that while 
discontinuation of the ICI results in resolution of the irAE, 
long courses of medications specific to the autoimmune reac-
tion may be needed to mitigate the effects of ICI therapy.11–13 
In a large systematic review of 251 cases involving anti-
CTLA-4 and anti-PD-1 agents, approximately 52% of treated 
patients discontinued ICI therapy due to the irAEs.11 Less 
than 10% required no treatment for the irAE, whereas the 
remainder was treated with corticosteroids, infliximab (an anti-
tumor necrosis factor agent), or disease-modifying antirheu-
matic drugs. Death due to the irAEs occurred in 4.7% of 
patients. Cutaneous autoimmune reactions are commonly 
associated with ICI therapy, but a case report on 2 patients 
with metastatic melanoma illustrated that irAEs may not 
appear until long after initiation of therapy.13 An autopsy study 
presented an elderly patient with melanoma exhibiting a sys-
temic inflammatory response that affected multiple organ sites 
ultimately resulting in the death of the patient.14
Limitations
This study is subject to the limitations of all claims-based stud-
ies.15,16 Notably, claims data lack detailed information on labo-
ratory values or information on tumor staging, which may have 
influenced the outcomes of this study. This study was limited 
to a 1-year follow-up due to the availability of data and the 
heterogeneity and variation of time confounded with longer 
follow-up. This study is strengthened by a large sample size 
and the inclusion of both commercial and Medicare claims.
Conclusions
The exclusion of patients with autoimmune conditions from 
the approval studies of nivolumab and pembrolizumab resulted 
in a lack of clinical guidance for a large population of patients 
that oncologists must decide whether to treat or not. In late-
stage treatment of these cancers, the potential durable response 
associated with ICIs will need to be weighed against the wors-
ening of the patient’s autoimmune condition, a decision for 
which clinical trials have not provided a concrete answer. 
Future evaluation of real-world treatment patterns will be 
needed to assess ICI usage and response in patients with auto-
immune conditions.
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Table 1. Autoimmune disorders in patients with lung and renal cancer between the years 2009 and 2013.
AUTOIMMUNE DISORDER AMONG PATIENTS wITH LUNG CANCER 
wITH AUTOIMMUNE DISEASE, NO. (%)
AMONG PATIENTS wITH RENAL CANCER 
wITH AUTOIMMUNE DISEASE, NO. (%)
Rheumatoid arthritis 2653 (20.2) 1490 (18.1)
Psoriasis 527 (4.0) 402 (4.9)
Systemic lupus erythematosus 225 (1.7) 120 (1.5)
Systemic sclerosis 78 (0.6) 20 (0.2)
Sicca syndrome 115 (0.9) 70 (0.9)
Autoimmune NOS 37 (0.3) 20 (0.2)
Autoimmune hepatitis 59 (0.5) 72 (0.9)
Primary biliary cirrhosis 38 (0.3) 33 (0.4)
Celiac disease 71 (0.5) 51 (0.6)
Ankylosing spondylitis 506 (3.9) 402 (4.9)
Polymyalgia rheumatica 227 (1.7) 141 (1.7)
Addison’s disease 357 (2.7) 196 (2.4)
Ulcerative colitis 352 (2.7) 238 (2.9)
Crohn disease 258 (2.0) 208 (2.5)
Ménière disease 89 (0.7) 67 (0.8)
Hashimoto disease 89 (0.7) 67 (0.8)
Polyarteritis nodosa 174 (1.3) 89 (1.1)
Giant-cell arteritis 93 (0.7) 45 (0.6)
Pernicious anemia 710 (5.4) 301 (3.7)
Autoimmune hemolytic anemia 39 (0.3) 22 (0.3)
Idiopathic thrombocytopenic purpura 152 (1.2) 82 (1.0)
Thyrotoxicosis 157 (1.2) 100 (1.2)
Multiple sclerosis 200 (1.5) 103 (1.3)
Iridocyclitis 280 (2.1) 209 (2.5)
Pemphigus 32 (0.2) 33 (0.4)
Eczema 312 (2.4) 288 (3.5)
Alopecia Areata 34 (0.3) 26 (0.3)
Vitiligo 18 (0.1) 29 (0.4)
wegener granulomatosis 28 (0.2) 21 (0.3)
Dermatopolymyositis 33 (0.3) 10 (0.1)
Myasthenia gravis 89 (0.7) 58 (0.7)
Scleroderma 62 (0.5) 47 (0.6)
Antiphospholipid 3 (0.0) 5 (0.1)
Guillain-Barré syndrome 28 (0.2) 23 (0.3)
Type 1 diabetes mellitus 1507 (11.5) 1189 (14.5)
Hypothyroidism 7334 (55.8) 4661 (56.7)
Hyperthyroidism 157 (1.2) 100 (1.2)
Sweet syndrome 215 (1.6) 183 (2.2)
Sjögren syndrome 115 (0.9 70 (0.9)
Pyoderma gangrenosum 7 (0.1) 1 (0.0)
Sarcoidosis 249 (1.9) 129 (1.6)
Abbreviations: NOS, Not Otherwise Specified.
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 NO. (%) NO. (%)
Age categories, y
 <65 8393 (39.3) 25 672 (43.0) <.0001
 65-74 6439 (30.1) 16 762 (28.1) <.0001
 75-80 3545 (16.6) 9276 (15.5) <.0001
 >80 2996 (14.0) 8049 (13.5) <.0001
Gender (F) 12 133 (56.8) 25 140 (42.1) <.0001
CHF 2938 (13.8) 6860 (11.5) <.0001
Arrhythmias 5530 (25.4) 13 659 (22.9) <.0001
Valvular disease 2986 (14.0) 6920 (11.6) <.0001
Pulmonary circulation 1150 (5.4) 2953 (4.9) .0119
Peripheral vascular 5812 (27.2) 14 187 (23.7) <.0001
Hypertension uncomplicated 13 814 (64.6) 35 614 (59.6) <.0001
Hypertension complicated 2375 (11.1) 5067 (8.5) <.0001
Paralysis 211 (1.0) 584 (1.0) .899
Other neurological 1919 (9.0) 4231 (7.1) <.0001
Chronic pulmonary 9063 (42.4) 25 053 (41.9) .2219
Renal failure 3085 (14.4) 6130 (10.3) <.0001
Liver disease 2528 (11.8) 6767 (11.3) .047
Peptic ulcer disease 308 (1.4) 772 (1.3) .1032
HIV/AIDS 33 (0.2) 116 (0.2) .2445
Metastatic cancer 4340 (20.3) 15 952 (26.7) <.0001
Coagulopathy 1145 (5.4) 2332 (3.9) <.0001
Obesity 1598 (7.5) 3402 (5.7) <.0001
weight loss 1599 (7.5) 4778 (8.0) .0165
Fluids and electrolytes 3549 (16.6) 8679 (14.5) <.0001
Blood loss anemia 990 (4.6) 2075 (3.5) <.0001
Deficiency anemia 1358 (6.4) 2835 (4.7) <.0001
Alcohol abuse 278 (1.3) 1087 (1.8) <.0001
Drug abuse 246 (1.2) 624 (1.0) .1933
Psychoses 397 (1.9) 1148 (1.9) .5595
Depression 2713 (12.7) 5888 (9.9) <.0001
CHD 5791 (27.1) 14 702 (24.6) <.0001
Abbreviations: CHF, congestive heart failure; CHD, coronary heart disease; HIV, human immunodeficiency virus.
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